Blog Reports
Check DailyStock reports by date and topic.
-
'100T Won Integrated Energy Giant with 1T Won Annual Cash Engine' SK Innovation (096770), SK E&S Merger Settlement and Financial Rebalancing Scenarios
SK Innovation completes its merger with SK E&S, building a 100T won energy giant. The influx of stable cash flows eases SK On's CAPEX pressure, drivin...
-
![[Nasdaq Stories] From Silicon to Systems: Assessing Synopsys (SNPS) EDA Monopoly in AI Semiconductors Post-Ansys Acquisition](https://daily-stock.kr/stdaily/uploads/202609/gen_6aac7f25ba9d84.16784737.png)
[Nasdaq Stories] From Silicon to Systems: Assessing Synopsys (SNPS) EDA Monopoly in AI Semiconductors Post-Ansys Acquisition
Synopsys completed its $35B Ansys deal, creating an end to end platform from chip logic to multi physics simulation. We analyze its expanded $31B TAM,...
-
'Dominating Defense AI Command and Government Pipeline' Palantir (PLTR) AIP Momentum and Tri-Regional Decoupling Analysis
Palantir PLTR accelerates government contracts by deeply integrating AIP into core DoD systems, backed by Maven and TITAN. As global markets face tri ...
-
![[KOSPI Stories] '500,000-Unit Sprint in India & 35% TSR Pledge': Kia (000270), Local Subsidiary Revaluation and Shareholder Value-Up Roadmap](https://daily-stock.kr/stdaily/uploads/202609/gen_6aab9021a564a0.62892738.png)
[KOSPI Stories] '500,000-Unit Sprint in India & 35% TSR Pledge': Kia (000270), Local Subsidiary Revaluation and Shareholder Value-Up Roadmap
Kia gains spotlight amid potential India subsidiary revaluation following Hyundai's IPO, backed by a robust 3 year roadmap committing to a 35%+ TSR, m...
-
![[Nasdaq Story] Casgevy Crosses the Monetization Inflection Point: Vertex (VRTX) Gene-Editing Commercialization Timeline and Valuation Review](https://daily-stock.kr/stdaily/uploads/202609/gen_6aab2da83d1375.41240614.png)
[Nasdaq Story] Casgevy Crosses the Monetization Inflection Point: Vertex (VRTX) Gene-Editing Commercialization Timeline and Valuation Review
Vertex Pharmaceuticals' CRISPR therapy Casgevy has entered an active revenue ramp up phase, easing initial launch delay concerns. Strong CF cash flow ...
-
'Peak NIM Debate and a 3.2x P/TBV Premium': JPMorgan Chase (JPM) Diagnosis and Financial Sector Valuations Amid Global Monetary Divergence
JPMorgan Chase commands an industry leading fortress balance sheet, but a 3.2x P/TBV premium and questions over peak NIM amid diverging global monetar...